Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Total Current Liabilities (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed Total Current Liabilities for 6 consecutive years, with $65.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 23.83% to $65.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $65.8 million, a 23.83% increase, with the full-year FY2025 number at $65.8 million, up 23.83% from a year prior.
  • Total Current Liabilities was $65.8 million for Q4 2025 at PROCEPT BioRobotics, up from $53.9 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $65.8 million in Q4 2025 to a low of $14.2 million in Q3 2021.
  • A 5-year average of $38.4 million and a median of $40.0 million in 2023 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 120.26% in 2023, then increased 0.47% in 2025.
  • PROCEPT BioRobotics' Total Current Liabilities stood at $16.2 million in 2021, then skyrocketed by 117.28% to $35.3 million in 2022, then surged by 30.14% to $45.9 million in 2023, then rose by 15.69% to $53.1 million in 2024, then rose by 23.83% to $65.8 million in 2025.
  • Per Business Quant, the three most recent readings for PRCT's Total Current Liabilities are $65.8 million (Q4 2025), $53.9 million (Q3 2025), and $49.7 million (Q2 2025).